Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Ivermectin in Crusted Scabies
NCT02841215Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CHILD-IVITAB in crusted scabies (CS) and scabies (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Rate of a successful treatment defined by two negative parasitologic and/or two dermoscopic exams at 21 days and Rate of a successful treatment defined by a clinical response at 28 days. Started Oct 2017; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
crusted scabies (CS)scabies
Beyond the preview
Go deeper on NCT02841215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841215.